HIV viral load monitoring

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 199-212

  Richman, D ^a   Crowe, S ^a   Harvey, K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; VIRUS RNA;

BLOOD ANALYSIS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TECHNIQUE; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033281795     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_19     Document Type: Conference Paper

References (61)

1. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
2. Association of plasma human immunodeficiency virus type I RA level with risk of clinical progression in patients with advanced infection
3. HIV viral load markers in clinical practice
4. Plasma viral load and CD4+ lymphocytes as prognostic markers of HV-1 infection
5. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions
6. Reduction in plasma human immunodeficiency virus ribonucleic acid following dideoxynucleoside therapy as determined by the polymerase chain reaction
7. Competitive polymerase chain reaction assay for quantitation of HIV-1 DNA and RNA
8. The application of quantitative polymerase chain reaction to therapeutic monitoring
9. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma; application to acute retroviral infection
10. Comparitive Evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV Monitor, and QUANTIPLEX HIV RNA Assay, Three methods for quantification of human Immunodeficiency virus type 1 RNA in plasma
11. A rapid and simple sample preparation method dramatically increases sensitivity of HIV-1 plasma RNA assay
12. Performance of the amplicor HIV-1 monitorTM test and a modified HIV-1 monitor test on HIV-1 subtypes A to F
13. Direct and quantitative detection of HIV-1 RNA in human plasma with branched DNA signal amplification assay
14. Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology
15. An enhanced sensitivity branched DNA (ES bDNA) assay for the quantification of HIV-1 RNA in plasma
16. Signal amplification: A direct approach to viral quantitation
17. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days
18. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
19. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml
20. Nucleic acid sequence based amplification
21. NASBA technology: Isothermal RNA amplification in qualitative and quantitative diagnostics
22. A one tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes
23. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
24. Application of branched DNA signal amplification to monitor human immunodeficiency virus type I burden in human plasma
25. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection
26. Assessment of a standardized reverse transcriptase PCR assay for quantifying HIV-1 RNA in plasma and serum
27. Detection of low HIV-1 RNA levels in plasma
28. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma
29. Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1 infected patients
30. Sensitive detection and early prognostic significance of p24 antigen in heat denatured plasma of human immunodeficiency virus type I infected infants
31. Simple monitoring of antiretroviral therapy with a signal amplification boosted HIV-1 p24 antigen assay with heat denatured plasma
32. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma
33. Rapid and precise quantification of HIV-1 RNA in plasma with use of a branched DNA signal amplification assay
34. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with ≥ 400 CD4 lymphocytes; implications for applying measurements to individual patients
35. Diurnal and short term stability of HIV virus load as measured by gene amplification
36. Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA-QT
37. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes
38. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction
39. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection; a mathematical model
40. Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma
41. Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regard to different HIV-1 subtypes
42. Subtype-specific problems with quantification of plasma HIV-1 RNA
43. Cerebrospinal fluid HIV-1 RNA levels correlate with AIDS dementia complex
44. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma; comparison of NASBA with Amplicor reverse transcription PCR amplification and correlation with quantitative culture
45. High viral load in semen of human immunodeficiency virus type 1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
46. + lymphocytes as prognostic markers of HIV-1 infection
47. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection
48. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
49. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
50. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
51. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifetime, and viral generation time
52. Decay characteristics of HIV-1-infected compartments during combination therapy
53. Quantitative image analysis of HIV-1 infection in lymphoid tissue
54. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
55. The durability of response to protease inhibitor therapy is predicted by viral load
56. Reduction of HIV-1 in blood and lymph nodes following potent anti-retroviral therapy and the virologic correlates of treatment failure
57. HIV replication and genotypic resistance in blood and lymph nodes after one year of potent antiretroviral therapy
58. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
59. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
60. HIV viral load markers in clinical practice
61. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel